Merge Healthcare's Cedara Software division has signed an agreement with Molecular Therapeutics of Ann Arbor, MI, to market and sell software for functional diffusion mapping.
Functional diffusion mapping uses MRI to track changes in the physiological activity of tumors through changes in water diffusion and Brownian motion. The technique could be used for targeted treatment planning and to evaluate tumor response to radiation therapy and anticancer drugs.
The technology was developed by Brian Ross, Ph.D., at the University of Michigan, and was licensed to Molecular Therapeutics. A paper published in the March 2005 edition of the Proceedings of the National Academy of Sciences indicated that functional diffusion mapping could allow researchers to evaluate tumor response at a "significantly earlier stage" than currently possible, according to Cedara.
Molecular Therapeutics researchers will work with Cedara to investigate how the technology can affect patient outcomes, and Cedara will focus on commercializing the product, receiving regulatory clearance, and marketing the technology to OEMs. Merge's Merge eMed division will concentrate on bringing the technology to end users such as hospitals and imaging centers, the company said.
By AuntMinnie.com staff writers
June 22, 2005
Related Reading
Cedara introduces clinical applications, June 20, 2005
Merge changes name to Merge Healthcare, June 10, 2005
Cedara B-CAD nets FDA clearance, June 2, 2005
Merge eFilm, Cedara close deal, June 1, 2005
Court approves Cedara merger with Merge, May 27, 2005
Copyright © 2005 AuntMinnie.com
